Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F. Seymour, Andrew W. Roberts, Shuo Ma et al.|The Lancet Oncology|2017Cited by 327
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapySteven Coutré, Matthew S. Davids, Michael Y. Choi et al.|Blood|2018Cited by 132
Successful Nonoperative Management of the Most Severe Blunt Renal InjuriesGwendolyn M. van der Wilden, Marc A. de Moya, Adrian A. Maung et al.|JAMA Surgery|2013Cited by 129
Successful Nonoperative Management of the Most Severe Blunt Liver InjuriesGwendolyn M. van der Wilden, Yuchiao Chang, George C. Velmahos et al.|Archives of Surgery|2012Cited by 93
Statins enhance efficacy of venetoclax in blood cancersJ. Scott Lee, Andrew W. Roberts, Dennis Juarez et al.|Science Translational Medicine|2018Cited by 86